With
the recent FDA approval of Tavenos™ for ANCA-associated vasculitis, myeloid
cells have become an attractive target for pharmacological interventions, being
developed for the treatment of various oncological disorders
Roots Analysis has announced
the addition of “Myeloid Cell Targeting Therapeutics
arket,
2021-2035” report to its list of offerings.
With ever increasing cancer
burden, the focus of the research community has shifted towards the development
of alternatives for the traditional anticancer therapies, such as myeloid cell
targeting therapeutics. Myeloid cells, with their multifaceted functions and
abundance in tumor microenvironment can be easily targeted and have emerged as
novel therapeutic candidates for the treatment of several oncological disorders
in combination with chemotherapy and radiotherapy.
Key
arket Insights
Presently,
more than 100 drug candidates are being evaluated across different phases of
development
Over 70% of the pipeline
candidates are currently being evaluated in clinical stages; of these, more
than 35 candidates are in phase I of their clinical trials. This is followed by
25% therapies being investigated in preclinical and discovery stages. It is
worth highlighting that majority of the therapy candidates (53%) are biologics.
More
than 380,000 patients have been enrolled in over 1,500 clinical trials,
worldwide
Clinical research activity,
in terms of number of trials registered, is reported to have increased over the
last five years. Of the total number of trials, close to 65% have already been
completed, while 22% are active and still recruiting patients.
Get
Detailed Report: https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html
Close
to 10,000 articles focused on myeloid cells have been published, since 2016
Owing to the rising research
efforts by several industry and non-industry players engaged in this domain, a
number or peer reviewed articles have been published in reputed scientific
journals. It is worth highlighting that, in 2021 (till June) 935 articles
related to myeloid cells targeting therapeutics were published; of these more
than 70% are research articles.
Close
to 30 partnerships have been inked among various industry and non-industry
players between 2017 and 2021
Maximum number of
partnerships were established in 2021, indicating a recent rise in the interest
of players engaged in this domain. It is worth highlighting that, majority of
the deals were R&D agreements, representing over 25% of the total number of
partnerships signed.
Close
to USD 5 billion has been invested by both private and public investors, since
2017
Of the total amount
invested, over USD 2 billion was raised through secondary offering,
representing over 58% of the overall funding activity in this domain. Further,
20 instances of venture capital funding were also reported, wherein players
collectively received more than USD 750 million.
North
America and Europe are anticipated to capture larger share of the market share
by 2035
Growth in this domain is
anticipated to be driven by the drugs that are being developed for the
treatment of oncological and rare disorders. It is worth mentioning that
myeloid cells targeting therapeutics market for small molecules is likely to
capture over 70% of the total market share by 2035.
Request
for Customization @ https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market/request-customization.html
Key
Questions Answered
· Who are the leading players engaged in the
development of myeloid cells targeting therapeutics?
· Which are the key drugs being developed
across early and late stages of development?
· Which companies are actively involved in
conducting clinical trials for myeloid cell targeting therapeutics?
· What is the focus of various publications
related to therapeutics targeting myeloid cells?
· What kind of partnership models are commonly
adopted by industry stakeholders engaged in the myeloid cells targeting
therapeutics domain?
· How is the current and future opportunity
likely to be distributed across key market segments?
The
financial opportunity within the myeloid cells targeting therapeutics market
has been analyzed across the following segments:
Type
of Molecule
· Small Molecule
· Biologics
Type
of Therapeutic Area
· Oncological Disorders
· Rare Disorders
Type
of Therapy
· Combination Therapy
· Monotherapy
Route
of Administration
· Intravenous
· Oral
Key
Geographical Regions
· North America
· Europe
· Asia Pacific
The
report features inputs from eminent industry stakeholder(s), who were very
optimistic concerning the development of myeloid cells targeting therapeutics.
The report includes detailed transcripts of the discussions held with the
following industry experts:
· Rene Hoet (Chief Scientific Officer, Montis
Biosciences)
· Tom Wilton (Chief business Officer, Carisma
Therapeutics)
The
research also includes detailed profiles of the companies (listed below)
engaged in developing therapies targeting myeloid cells; each profile features
an overview of the company, its financial information (if available), details
on product portfolio, recent developments, and an informed future outlook.
· AstraZeneca
· ChemoCentryx
· Daiichi Sankyo
· Enlivex
· Gilead
· GlaxoSmithKline
· Immune-Onc Therapeutics
· Infinity Pharmaceuticals
· Jansen
· Macrophage Pharma
· Pfizer
· Roche
Request
for Sample: https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market/request-sample.html
Read
Our Latest Blogs:
Visit
for More Insights: https://www.rootsanalysis.com/reports.html
Read
Our Latest Press Release: https://www.rootsanalysis.com/press-releases.html
Latest
Blogs On Healthcare Industry: https://www.rootsanalysis.com/blog/
Our
Service Portfolio: Pipeline Tracking | Publication Analysis | Investment Analysis | Market Assessment | Competitive Profiling | Commercial Strategy and Business
Development
About
Roots Analysis
Roots
Analysis is
one of the fastest growing market research companies, sharing fresh and
independent perspectives in the bio-pharmaceutical industry. The in-depth
research, analysis and insights are driven by an experienced leadership team
which has gained many years of significant experience in this sector.
Contact
Information
Roots
Analysis Private Limited
Ben
Johnson
+1
(415) 800 3415
+44
(122) 391 1091
Ben.johnson@rootsanalysis.com